Aurobindo Pharma moves Russian unit Auro Pharma LLC between subsidiaries

Aurobindo Pharma (NSE: AUROPHARMA) has approved the transfer of Auro Pharma LLC, Russia, from one wholly owned subsidiary to another, it said in a filing on 04 Nov 2026. The company describes the move as part of an internal reorganization of the Russian subsidiary's holdings within the group.

What is moving and between whom

Auro Pharma LLC is a step-down subsidiary of Aurobindo Pharma, incorporated in Russia on 24 Jul 2023 to manufacture and market pharmaceutical products. Its 100% stake is held by Auroactive Pharma Private Limited, a wholly owned subsidiary of the company. The proposal moves that entire stake to Auropharm Overseas Limited, also a wholly owned subsidiary.

The company's board approved the proposal at a meeting held on 4 Nov 2026, and the boards of the two subsidiaries approved it as well. Because both parties are wholly owned subsidiaries, the filing notes that the deal is exempt from certain related-party rules under the SEBI Listing Regulations.

Price, timing and approvals

The cash consideration is approximately ₹29 crore, subject to adjustments agreed between the parties as on the date of transfer. The indicative completion period is 60 to 90 days, subject to customary corporate and transfer formalities.

Auroactive Pharma reported turnover of ₹70.13 crore for the financial year ended 31 Mar 2026. Auro Pharma LLC reported nil turnover for FY 2026, FY 2025 and FY 2024, and Auropharm Overseas reported nil turnover for FY 2026.

What the transfer means for Aurobindo Pharma's shareholders

The move changes which group company holds the Russian subsidiary and does not, on the filing's terms, change the company's ownership of it. The company is a Hyderabad-based drugmaker with a market value of about ₹98,106 crore, and its latest quarter reported total income of ₹9,414.58 crore, so the ₹29 crore consideration is small against that base.

Not stated: the reason the stake is moving to Auropharm Overseas rather than staying in its current holder, the financial effect on the company's results, and whether the consideration will be paid in one instalment. The next dated step is completion, expected within 60 to 90 days of the filing.

At a glance